HMGA1及KRAS与妇科肿瘤的相关性

Correlation between HMGA1 and KRAS with gynecological tumors

随着社会经济水平的提高及人们对健康需求的重视,女性的身体健康逐渐受到社会的广泛关注。然而,妇科肿瘤的发病率及致死率仍居高不下,关于妇科肿瘤的发病机制及治疗仍存在较大争议。相关研究表明,高迁移率族蛋白A1(HMGA1)及Kirsten大鼠肉瘤病毒癌基因同源物(KRAS)作为癌基因,能通过参与多种途径在肿瘤的发生、发展中发挥重要的作用。HMGA1及KRAS也被证实在癌症的诊断、治疗及预后中可作为潜在的分子标志物,亦可作为治疗靶点,提高药物疗效。本文首先对两种基因的研究过程进行系统回顾,然后阐述其在部分常见妇科肿瘤疾病发展过程中所发挥的作用,最后探讨其对妇科肿瘤的治疗及预后的影响,希望可以为HMGA1及KRAS的研究提供相关依据。

With the improvement of social and economic level and people's attention to health needs,women's health has gradually received extensive attention from the society.However,the incidence and mortality of gynecological tumors are still high,and there is still a great controversy about the pathogenesis and treatment of gynecological tumors.Relevant studies have shown that,high mobility group protein A1(HMGA1)and Kirsten rat sarcoma viral oncogene homolog(KRAS)as oncogenes,can play an important role in the incidence and development of tumors by participating in a variety of ways.HMGA1 and KRAS have also been proved to be potential molecular markers in the diagnosis,treatment and prognosis of cancer,and can also be used as therapeutic targets to improve drug efficacy.In this paper,we first systematically review the research process of the two genes,then explain their role in the development of some common gynecological tumors diseases,and finally explore their effects on the treatment and prognosis of gynecological tumors,hoping to provide relevant basis for the study of HMGA1 and KRAS.